Market Newsdesk

SILICON SLOPES, Utah, March 31, 2021 (GLOBE NEWSWIRE) — Pluralsight, Inc. (NASDAQ: PS), the technology workforce development company, today announced that the company is bringing back Free April, allowing 30 days of free access to the Pluralsight Skills platform for individuals and businesses during the month of April.

Last year, Pluralsight introduced the Free April program to encourage technology learners to stay home, stay safe, and skill up as the pandemic raged. This year, Pluralsight is once again offering Free April to help businesses accelerate their recovery from the effects of the pandemic through enterprise upskilling and reskilling programs and individuals focus on skill development to ready themselves for the next stage of their career path.

“A year ago, we saw tremendous impact with Free April, as more than a million technologists used Pluralsight Skills to develop new capabilities as the COVID-19 pandemic impacted us all. This year, we see tremendous opportunity for Pluralsight to help accelerate our global economic recovery by helping both businesses and individuals get access to our platform,” said Aaron Skonnard, co-founder and CEO, Pluralsight. “Businesses and individuals that focus on reskilling and upskilling to improve their technology acumen will be better positioned to grow and find success in today’s post-pandemic digital economy.”

For businesses wishing to participate in Free April, Pluralsight is offering a 30-day pilot of its technology skills platform that will enable teams to develop skills at scale. Additionally, Pluralsight is offering free instructor-led training programs for enterprises participating in Free April pilots. Details on how businesses can participate in Free April can be found here.

Individual learners that want to take advantage of Free April to improve their technology skills can register for an account here. As part of the promo, technologists will have access to the Pluralsight Skills library of on-demand video content taught by the world’s foremost experts in their respective technology fields. Additionally, learners will have access to a number of interactive courses and projects as well as skill assessments to help them develop the most effective path to learn and implement new technology skills.

For more information about how Pluralsight helps businesses and individuals develop technology skills in the most efficient manner possible, please visit www.pluralsight.com.

About Pluralsight

Pluralsight is the leading technology workforce development company that helps companies and teams build better products by developing critical skills, improving processes and gaining insights through data, and providing strategic skills consulting. Trusted by forward-thinking companies of every size in every industry, Pluralsight helps individuals and businesses transform with technology. Pluralsight Skills helps enterprises build technology skills at scale with expert-authored courses on today’s most important technologies, including cloud, artificial intelligence and machine learning, data science, and security, among others. Skills also includes tools to align skill development with business objectives, virtual instructor-led training, hands-on labs, skill assessments and one-of-a-kind analytics. Flow complements Skills by providing engineering teams with actionable data and visibility into workflow patterns to accelerate the delivery of products and services. For more information about Pluralsight (NASDAQ: PS), visit pluralsight.com.

Media Contact

Pluralsight PR

Dan Sorensen
Director of Communications
[email protected]

VANCOUVER, British Columbia, March 31, 2021 (GLOBE NEWSWIRE) — Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular booster systems, is pleased to announce it has closed its previously announced acquisition, through a wholly-owned subsidiary, of all the issued and outstanding shares of ClearRF, LLC (ClearRF), for a total purchase price of US$700,000 with a combination of cash and shares.

Headquartered in Spokane, Wash., ClearRF produces M2M (machine-to-machine) cellular amplifiers for commercial and industrial M2M applications. ClearRF enables companies to deploy telemetry systems, remotely monitor and control their M2M applications in real-time and its products combine world-class innovation and industry experience and are designed and manufactured in the U.S.

ClearRF also offers patented direct connect cellular amplifiers designed for M2M and “internet-of-things” (IoT) applications, specifically for fixed and mobile M2M applications to connect directly to any cellular router, modem, embedded module or alarm. ClearRF amplifiers provide a consistent, strong cellular signal in low or intermittent signal-challenged environments.

About Siyata Mobile

Siyata Mobile Inc. is a Business-to-Business (B2B) global vendor of next generation PoC devices and cellular booster systems. Its portfolio of in-vehicle and rugged smartphones enables first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to improve communication, increase situational awareness, and save lives.

Its portfolio of enterprise cellular booster systems enables first responders and enterprise workers to amplify its cellular signal in remote areas, inside structural buildings where signals are weak, and within vehicles for maximum cellular signal strength possible.

Siyata’s common shares trade on the Nasdaq under the symbol “SYTA” and its warrants under the symbol “SYTAW”.

Visit siyatamobile.com and unidencellular.com/ to learn more.

Investor Relations (Canada):

Kin Communications
1-866-684-6730
[email protected]

Investor Relations (United States)

CORE IR
516-222-2560
[email protected]

Sales Department:

Glenn Kennedy, VP International Sales
Siyata Mobile Inc.
416-892-1823
[email protected]

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

NASHUA, N.H., March 31, 2021 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound^® AI for 2D Mammography might notably reduce the risk of interval breast cancer, according to a retrospective analysis recently published in the Journal of Medical Screening.¹

The aim of the study was to determine if adding AI to reading mammography as a supportive tool may help in decreasing the interval cancer rate in population-based organized mammography screening programs in Germany.

“Interval breast cancers—cancers that are diagnosed after a negative mammography screening, but before the next recommended screening exam, can be linked to a poor prognosis such as cancer that has already spread, or a more aggressive type of cancer, thus underscoring the need for iCAD’s deep-learning algorithm that can analyze each mammography image and provide critical insight into individual cases,” said Michael Klein, Chairman and CEO of iCAD. “The data from this retrospective analysis are very encouraging in Europe while also having an impact on screening in the US. The results further stress the importance of our ProFound AI platform as a world-class artificial intelligence (AI) solution offering benefits to radiologists and women in improving breast cancer detection rates, reducing false positives and unnecessary callbacks, and providing more personalized screening for every woman.”

In the retrospective analysis, which evaluated a screening period from 2011 and 2012, a total of 37,367 women between the ages of 50-69 were screened with full-field digital mammography (FFDM). Of these, 29 cases of interval cancers with full documentation were evaluated using ProFound AI for 2D Mammography. For quality assurance, interval cancers with the prior screening mammogram were classified in four categories by the radiologists: true interval cancers, minimal sign cancers, missed cancers (false negative) based on the original screening exam deemed as normal and dismissed, and occult cancers. The objective of the study was to determine whether ProFound AI for 2D Mammography could identify interval cancers that had either minimal signs in the original normal screening or were missed in the original screening round where they had been dismissed as a normal exam.

According to the lead author of the study, Axel Gräwingholt, MD, Radiologie am Theater in Paderborn, Germany, “The results indicate that ProFound AI for 2D Mammography found 93% of these cancers—eight out of nine cancers that presented minimal signs and six out of six that were false negatives, or missed in the screening round—demonstrating that some cancers could have been detected earlier within the screening round where they were dismissed as normal and therefore wouldn’t have been detected as interval cancers.”

“As a result, ProFound AI as a clinical tool for radiologists has the potential to reduce interval cancer rates by detecting cancers that are already present in the screening round but are perhaps undetected or missed by the readers,” continued Dr. Gräwingholt. “Using this technology at the screening level could limit the number of false negatives and help to detect a large proportion of the minimal sign cancers, which could ensure earlier treatment and better chances of recovery for these women.”

“This study contributes to the growing body of evidence that demonstrates the clear value ProFound AI for 2D Mammography can offer to screening programs across Europe, benefiting both the patient and the clinician,” said Michele Debain, Vice President of Europe, Middle East and Africa at iCAD. “It is essential to detect breast cancers as early as possible, as the cancer can grow, develop and spread. Earlier cancer detection allows for earlier treatment, which in turn could lead to less stress for the patient and lower costs for the national health systems. In addition, the rate of interval cancers is typically used as a measure for the quality of the national mammography screening program.”

iCAD’s Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT) and software solutions for 2D mammography, risk evaluation and breast density. In 2018, ProFound AI for DBT received its CE mark, Health Canada approval and was the first 3D tomosynthesis software using AI to receive clearance from the U.S. Food and Drug Administration (FDA). ProFound AI for 2D Mammography received a CE mark in July 2019. In a reader study published in Radiology, ProFound AI for DBT was shown to offer clinically proven time-savings benefits to radiologists, reducing reading time by 52.7 percent, improving radiologist sensitivity by 8 percent, and reducing false positives and unnecessary patient recall rates by 7.2 percent.²

Dr. Axel Gräwingholt’s Biography

Dr. Axel Gräwingholt is a radiologist specializing in breast imaging. He is a co-owner of a private radiology institute in Germany with a screening unit for the German official breast cancer screening program, and he is also involved in several screening programs in Europe as a reader (Germany, Switzerland, Norway). Dr. Gräwingholt also participated in the TOSYMA trial in Germany to assess the value of tomosynthesis in organized screening programs. He is clinical co-chair of the European guidelines for breast cancer (ECIBC), and he is a lecturer on courses about mammography and tomosynthesis screening in different countries, including Switzerland, Armenia, China and Greece.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com and www.xoftinc.com.

Forward-Looking Statements

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the benefits of the Company’s agreement with Solis and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov. 

Contacts:

Media inquiries USA:
Jessica Burns, iCAD
+1-201-423-4492
[email protected]

Media inquiries Europe:
Emmanuelle Vella, iCAD
+33 620 49 48 57
[email protected]

Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568
[email protected]

¹ Graewingholt A, Rossi PG. (2021). Retrospective analysis of the effect on interval cancer rate of adding an artificial intelligence algorithm to the reading process for two-dimensional full-field digital mammography. J Med Screen. 0(0) 1-3.
Accessed via https://journals.sagepub.com/doi/10.1177/0969141320988049
² Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Company management will participate in the following virtual conferences:

• Wells Fargo Biotech Corporate Access Day (April 6, 2021)
  Sue Washer, President & Chief Executive Officer, and Bill Sullivan, Chief Financial Officer, will host investor one-on-one and small group meetings. For more information, please contact your Wells Fargo representative.

• Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean (April 6-9, 2021)
  An AGTC corporate update by Ms. Washer and Mark Shearman, PhD, Chief Scientific Officer, will be available for registered attendees to view on-demand throughout the entirety of the conference. Please visit www.meetingonthemed.com for full information including registration.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

IR/PR Contacts:

David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
[email protected] or [email protected]

Corporate Contacts:

Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
[email protected]

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
[email protected] 

SAN FRANCISCO, March 31, 2021 (GLOBE NEWSWIRE) — PandaDoc, the leading all-in-one document automation software solution, is pleased to announce an enterprise partnership with business management and financial services company, Account Control Technology Holdings (ACT Holdings). PandaDoc has helped ACT Holdings achieve instrumental success with streamlining lengthy hiring and onboarding processes using PandaDoc Forms, the company’s latest product enhancement that eliminates the need for paper forms by providing a secure solution for capturing personal data with legally binding and compliant eSignatures.

ACT Holdings made the switch to PandaDoc after previously using another more costly eSignature product. PandaDoc was selected for its overall ease of use, depth of capabilities and predictable per-user pricing with unlimited documents. Crucial to their decision to use PandaDoc was the new Forms functionality, which has saved the human resources team about 40 hours a week of work and countless errors due to manual data entry.

“PandaDoc has freed up time for us to do other parts of our jobs that were neglected because we were inundated with paperwork,” said Amanda Rominger, Director of Talent Acquisition at ACT Holdings, Inc. “PandaDoc Forms has significantly improved our ability to onboard new candidates faster, which is especially important when you can’t have people face to face in the office. With this improved onboarding process, the team can now focus on our massive hiring pool.”

The human resources department for ACT Holdings hires over 400 people monthly. The lean, mostly remote-working HR team had been manually sending paper documents for offer letters, onboarding paperwork, and company handbooks, which wasted the team’s time when it came time to file paperwork and locate specific documents for audits. ACT turned to PandaDoc Forms to digitize their documents in a secure and trackable central location with the added benefit of easily transferring communication from department to department.

Launched earlier this year, PandaDoc Forms offers an integrated and seamless way to create, share and collect forms of all types. From contracts and registration forms, to terms of service and non-disclosure agreements, to applications and human resources documents, organizations and teams of all sizes can use PandaDoc Forms by simply embedding it on a website or sharing it via direct link — no recipient email or coding experience necessary!

“We’re proud that PandaDoc Forms has helped ACT Holdings experience such drastic improvements to their processes. Their story exemplifies our commitment to offer customers a simple, convenient and efficient way to gather, record, manage and process information to support a variety of business functions,” said Bernard Desarnauts, VP of Product for PandaDoc. “As we continue to expand into new industries and use cases, particularly with those needing robust eSignature capabilities, this product is a critical next step in helping to automate our customer’s workflows.”

To learn more about how PandaDoc Forms makes data collection easy and fast or view a growing library of form templates to choose from, visit PandaDoc.com.

Read more about ACT Holdings and other PandaDoc case studies here.

About PandaDoc:

Founded in 2013, PandaDoc is an all-in-one document automation software that streamlines the process of creating, approving, and eSigning business documents, including proposals, quotes, and contracts. Backed by Microsoft Ventures, HubSpot, Altos Ventures and Rembrandt Venture Partners, PandaDoc was ranked on the 2020 Inc. 5000 list of America’s fastest growing companies as well as the Deloitte Technology Fast 500. Over 23,000 customers use the company’s powerful document creation and workflow capabilities. PandaDoc is proudly a remote-first global company. For more information, visit www.PandaDoc.com.

Media contact:
Amanda Tsang
[email protected]

ATLANTA, March 31, 2021 (GLOBE NEWSWIRE) — RestorePoint (www.restorepoint.ai), a metro Atlanta based technology leader in data management, integrated security and business analytics, is pleased to announce that it has added a new Data Control Center – Fusion – to its innovative PLASMA platform.

“PLASMA’s new Fusion module provides businesses the ability to easily control and automate data management functions in the PLASMA Platform,” says Scott Danner, Chief Customer Officer, RestorePoint. “Businesses want self-service capability to schedule data refresh, establish thresholds related to process automation and manage end user notifications – ultimately improving speed to value.”

With PLASMA Fusion, businesses can now connect, correlate, visualize, distribute, automate and control complex bi-directional data flow from multiple sources anytime, anywhere. To find out how your company can benefit, email us at [email protected] or visit our website www.restorepoint.ai.

About RestorePoint:

RestorePoint’s expertise is in data management, business intelligence and integrated security. RestorePoint’s PLASMA Platform has been adopted across many industries including service providers, commercial real estate, healthcare, higher education, manufacturing and financial services.

Contact Info:

Tracey Gaertner
[email protected]
404-918-7877

 

Epazz DeskFlex room scheduling software launches a vaccine management solution to simplify COVID-19 vaccination tracking in the workplace.

CHICAGO, March 31, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — EPAZZ Inc. DeskFlex (OTC: EPAZ), a leading provider of cloud-based, mission-critical software solutions, announced today the launching of the DeskFlex’s Vaccine Management solution for COVID vaccination initiatives among businesses and organizations.

At present, three (3) vaccines are FDA-approved and recommended to prevent contracting the virus. These include the Pfizer-BioNTech vaccine, Moderna vaccine, and Johnson & Johnson’s Janssen vaccine. With mass vaccination activities aiming to vaccinate at least 70% of the total population, several businesses and companies are doing their part in speeding up and tracking vaccination efforts among their staff and team members.

The DeskFlex Vaccine Management solution is one of its COVID compliant features that allow employees to notify the company about their vaccination status against the Covid19 virus. It monitors and tracks the employees’ vaccination history and their subsequent scheduled doses. It allows their team members to upload vaccination certificates to the system. It is an essential software feature to support contact tracing and uphold safety protocols in the workplace.

According to Shaun Passley, Ph.D., Chairman, and CEO of Epazz, Inc.,
“DeskFlex vaccine management solution will further secure the workplace and schools from COVID-19 infections. When administrators identify those who haven’t had the vaccine, they can make the appropriate decisions for the good of the majority.”

DeskFlex vaccine management software will remind the staff of their following vaccination schedule or upcoming booster shots by sending out email and text notifications. The system keeps accurate and updated details on the Vaccination Date, Vaccination Type, Required Booster Shot, Schedule of Booster Shot, Completed Booster Shot, and Date of Booster Shot Completion.

Using DeskFlex’s vaccine management solution, the company admins can manage their workforce well. With the employees’ submitted vaccination certificates, they can purposefully decide whether to revisit their health and safety protocols in the workplace and change their operations management.

DeskFlex’s vaccine management software aims to reinforce every workplace’s health and safety measures. DeskFlex desk booking software solution takes pride in providing industries with innovative COVID-compliant software features. Among the COVID-compliant features include Dynamic Scheduling, Capacity Limits, Manage Survey, Visitor Management, Bluetooth Beacons, Automatic Desk Sanitation, Contactless Room Displays, and many more.

About 


DeskFlex.com


 

DeskFlex is a desk booking solution and room reservation software useful in booking conference rooms, meeting rooms, workspaces, desks, car parking spaces, and office equipment. DeskFlex meeting room scheduling system helps office managers accommodate remote workers’ time in the office, reducing rent and facility costs. DeskFlex lets employees reserve desks in advance or claim desks right away. It adjusts the telephone switch (PBX), so calls ring at the “desk du jour.” DeskFlex includes check-in, point-and-click floor maps, a web browser, a local kiosk, Outlook integration, and conference room scheduling.

About


Epazz, Inc


. (www.epazz.com)

Epazz, Inc., is a leading cloud-based software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions, and the public sector. Epazz BoxesOS™ v3.0 is a complete web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz’s other products are K9Sky.com kennel software and the Provitrac applicant tracking system.

SAFE HARBOR

This is the “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by the use of forward-looking words such as “may,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” and “continue” (or the negation thereof) or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from future results or those implied by such forward-looking statements. Investors are cautioned that no forward-looking statement is a guarantee of future performance and that actual results may differ materially from those contemplated by such forward-looking statements. Epazz, Inc. assumes no obligation and has no intention of updating these forward-looking statements. It has no obligation to update or correct information prepared by third parties that are not paid for by Epazz, Inc. Investors are encouraged to review Epazz, Inc.’s public filings on SEC.gov and otcmarkets.com, including its unaudited and audited financial statements and its OTC market filings, which contain general business information about the company’s operations, results of operations, and risks associated with the company and its operations.

CONTACT: For more information, please contact

         Investor Relations

         [email protected]

         (312) 955-8161

         www.epazz.com

PALO ALTO, Calif., March 31, 2021 (GLOBE NEWSWIRE) — Mobile identity company, Incognia, today announced the availability of its Anti-Fraud Mobile SDK and APIs with two new integrations, Incognia Onboarding and Incognia Authentication, on the Auth0 Marketplace, a catalog of trusted technology integrations that extend the functionality of Auth0’s identity management platform. With rising rates of mobile fraud, Incognia provides advanced device intelligence and location behavior signals for enhanced identity verification and authentication for fintech and mcommerce mobile apps.

Incognia’s proprietary location technology works silently in the background to protect mobile users. Using network signals from GPS, Wi-Fi and Bluetooth along with on-device signals, Incognia builds an anonymous location behavioral pattern, unique for each user, which provides a private identity that is dynamic and extremely difficult for fraudsters to mimic or fake. As mobile usage is on the rise, Incognia enables fintech and mcommerce mobile apps to provide frictionless identity verification and authentication for seamless recognition of trusted users and fraud prevention. The Incognia Anti-Fraud Mobile SDK complements Auth0 Extensible Identity, and the ease in which customers can seamlessly integrate adjacent technologies to facilitate the successful execution of larger projects such as digital transformation, threat detection, compliance and customer conversion.

Key features of the Incognia Anti-Fraud Mobile SDK and APIs are real-time address verification, recognition of trusted locations and risk-based authentication based on device intelligence and location behavior. Incognia offers two solution integrations on the Auth0 Marketplace:

• 
  Incognia Onboarding
  : Streamlining mobile identity proofing using address verification
• 
  Incognia Authentication
  : Reducing friction at login using location behavioral biometrics

These integrations enable faster onboarding, reduce false positives, prevent account takeovers and increase payment acceptance rates on mobile. Incognia is enabled via an SDK and APIs that integrate rapidly on both Android and iOS devices. Data collected by the SDK is anonymized with hash and encryption techniques.

“With the rapid shift to mobile, Incognia offers banks, fintech and mcommerce companies the ability to recognize trusted users and detect fraud using location, one of the strongest trust signals available on mobile,” said André Ferraz, founder and CEO of Incognia. “We’re proud to be working with Auth0 as a best-in-class technology solution offered in their marketplace. As mobile fraud continues to rise, we’re enabling a superior mobile experience for users by providing a frictionless solution for address verification and risk-based authentication, all while ensuring user privacy.”

“It has been really exciting to work with Incognia on a newly-built partner integration for the launch of Auth0 Marketplace. This best-in-class solution adds an integral layer to our platform that provides our customers with greater choice and flexibility,” said Bill Lapcevic, VP of Business Development at Auth0. “After speaking with many customers, we have identified the types of integrations that matter to them, and we are so thrilled to have Incognia as a vetted and valuable vendor in the Auth0 Marketplace.”

All partner integrations are thoroughly vetted and verified for security and functionality by Auth0, and are easily discoverable for customers. Partners can participate in the growing demand for digital identity solutions and increase their visibility as part of the Auth0 Marketplace, and can learn more here: https://auth0.com/partners.

About Incognia

Incognia is a mobile identity company that enables advanced fraud prevention for mobile apps of banks, fintech and mcommerce companies. Using location behavioral biometrics, Incognia offers frictionless identity verification and authentication. Incognia’s location technology uses network signals and on-device sensors to deliver highly precise location information. By building an anonymous location behavioral pattern, unique for each user, Incognia creates a private digital identity for account security.

Incognia is privately held and headquartered in Palo Alto, California with teams in New York and Brazil.

Stay connected and follow Incognia on Twitter and LinkedIn.

About Auth0

Auth0 provides a platform to authenticate, authorize, and secure access for applications, devices, and users. Security and application teams rely on Auth0’s simplicity, extensibility, and expertise to make identity work for everyone. Safeguarding billions of login transactions each month, Auth0 secures identities so innovators can innovate, and empowers global enterprises to deliver trusted, superior digital experiences to their customers around the world.

For more information, visit https://auth0.com or follow @auth0 on Twitter.

Media Contacts:

Karbo Communications for Incognia
[email protected]

Auth0 Global Communications
[email protected]